A Phase 1, Open label, Single Ascending Dose Study of Intravenous and Oral Doses of BRN-002 to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Hydroxypropyl betadex (Primary) ; Hydroxypropyl betadex (Primary)
- Indications Atherosclerosis
- Focus Adverse reactions
- 02 Nov 2021 New trial record